Medical standards are advancing rapidly. In addition to relying on the continuous technological breakthroughs of medical personnel, drug research and development is also a key part, especially if it can improve the quality of life of patients and even increase survival rates, it is of great significance. In order to develop more new drugs that bring benefits to patients, strong clinical verification is behind them. In view of this, Taiwan's Bailingjia Ingelheim and Taipei Medical University are working together for the first time to combine Bailingjia Ingelheim's unique innovative research and development capabilities with the rich basic research momentum of the three hospitals of Beijing Medical University to jointly promote more clinical trials and look forward to benefiting in the future. More patients!
Peking Medical University pursues innovative breakthroughs and attaches great importance to clinical experiments
President Lin Jianhuang of Taipei Medical University said that in recent years, Peking University has focused on the development of artificial intelligence medical care, focusing on AI-medical imaging, AI-medication safety, and AI-precision sleep medicine, and the introduction of IBM Watson artificial intelligence treatment assistance system, combined with medical big data, medical Internet of Things and electronic wards and other software and hardware. The pursuit of innovative breakthroughs in medical treatment has attracted public attention.
In addition, precision medicine is also an important development trend. Clinical trials are an important part of the research and development of new drugs and can benefit the majority of patients. Peking University attaches great importance to clinical trials, and its three affiliated hospitals have all passed the most stringent international evaluation of clinical trials - the American Association for the Protection of Clinical Research Subjects (AAHRPP), and have also passed the International Medical Institutions Review (JCI) , creating an international-level clinical trial environment. Beijing Medical University has strong and powerful basic researchers who can propose research plans for innovative drugs and develop new treatment technologies for specific diseases. Qiu Jianzhi, general manager of Taiwan Bailingjia Ingelheim, said that "demonstrating value through innovation" has always been the company's spiritual indicator, and drug research and development is also a part of innovation, so it continues to spare no effort.
Bailinga Ingelheim signed a memorandum of cooperation with Beijing Medical University to promote more clinical trials
Bailinga Ingelheim has excellent drug innovation and research and development capabilities. Taipei Medical University has been rated as an excellent school for industry and academia many times and is already Taiwan's leading research and development unit in the medical and biotechnology industry. This time, through industry-academic cooperation, the two parties will promote more clinical trials in the future, with special emphasis on cancer, neurological diseases, and more. Diseases, thoracic medicine and other major fields, we look forward to benefiting more patients. President Lin Jianhuang said that this time the two parties signed a clinical trial cooperation memorandum, and they also look forward to creating more breakthrough clinical trial results through cooperation with Taiwan's Bailingjia Ingelheim. Fruitful results will be around the corner.
Show value through innovation! Realizing the spirit of "experimental table to hospital bed"
Qiu Jianzhi, general manager of Taiwan Bailingjia Ingelheim, said that "showing value through innovation" has always been the company's spiritual indicator, and drug research and development is also a part of innovation. , so we continue to spare no effort, and the average cost of clinical trials per day is as high as 300 million yuan, which shows that we attach great importance to clinical research. Abroad, Bailingjia Ingelheim also cooperates with many teaching units, such as the University of Texas MD Anderson Cancer Center, the Icahn School of Medicine at Mount Sinai, etc., all of which hope to develop new disease mechanisms and novel mechanisms through cooperation with university units. Treatment modalities or techniques.
However, in the past, domestic cooperation between pharmaceutical companies and hospital clinical research units mostly involved providing new drugs to hospital clinical research units for human trials to clarify the effectiveness of the drugs in practical applications. The hospital side communicates with each other in a relatively one-way manner. This cooperation with Beijing Medical University hopes to break this one-way communication framework, strengthen the combination of "medical research" and "clinical application", and even develop new drugs with maximum value, achieving "experimental table to hospital bed" ” spirit to benefit more patients in need. Bailinga Ingelheim Taiwan and Taipei Medical University signed a clinical trial cooperation memorandum for the first time. They also look forward to creating more breakthrough clinical trial results through cooperation with Bailinga Ingelheim Taiwan. Fruitful results will be around the corner.
Based in Taiwan, looking at the world, and contributing to the health of all mankind
Liang Youzhi, director of human resources research at Taipei Medical University, said that the biggest feature of Beijing Medical University is that it has excellent With basic R&D capabilities, the three affiliated hospitals have more than 3,000 beds and 590 full-time attending physicians, providing an excellent clinical trial environment. In particular, compared with other clinical trial centers, the integration of one university and three hospitals can break through the past one-way thinking and create a translational development from basic to clinical. In the process, it can also accelerate the two-way verification of clinical and basic, and can Effective application leads to new diagnostic and therapeutic methods and the development of more valuable drugs. I believe that in the future, it will not only benefit patients, but also be based in Taiwan and look at the world, making contributions to the health of all mankind.